Steven M. Lipkin, MD, PhD

Clinical Genetics (MD)
Steven Lipkin

GENETIC TESTING, WHOLE EXOME AND GENOME SEQUENCING FOR THE MANAGEMENT FOR ADULT GENETIC DISEASES INCLUDING LYNCH SYNDROME/HNPCC, FAMILIAL ADENOMATOUS POLYPOSIS, HEMOCHROMATOSIS, LI-FRAUMENI, JUVENILE POLYPOSIS, PEUTZ-JEGHERS SYNDROME AND OTHER DISORDERS
 

Dr. Lipkin is a board certified Medical Geneticist with a focus on genetic testing for gastrointestinal diseases, including the Lynch Syndrome, Familial Adenomatous Polyposis, Hemochromatosis and Hereditary Pancreatic Cancer among others. He is an authority on cancer genetic syndromes, with a particular emphasis on hereditary Gastrointestinal cancer syndromes. He is the author of MAPP-MMR, a bioinformatic program that is used to interpret whether Lynch syndrome missense variants are deleterious muations or benign polymorphisms. He practices at Weill Medical College of Cornell University and New York-Presbyterian Hospital. He trained in Internal Medicince at Duke University and Medical Genetics at the National Human Genome Research Institute.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [Medicare]
  • AETNA [PPO]
  • Aetna - Weill Cornell [POS]
  • CIGNA
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Medicare [Medicare]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Oxford Health Plans [Liberty]
  • Rockefeller University - CoreSource
  • United Health Care [Medicare]
  • United Health Care

Publications

SELECTED PUBLICATIONS



1. Lipkin SM, Wang V, Jacoby R, Banerjee-Basu S, Baxevanis AD, Lynch HT, Elliott RM, Collins FS. MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. Nat Genet 2000;24:27-35.



2. Lipkin SM, Wang V, Stoler DL, Anderson GR, Kirsch I, Hadley D, Lynch HT, Collins FS. Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: Evidence for somatic mutation in colorectal cancers. Hum Mutat 2001;17:389-96.



3. Lipkin SM, Moens PB, Wang V, Lenzi M, Shanmugarajah D, Gilgeous A, Thomas J, Cheng J, Touchman JW, Green ED, Schwartzberg P, Collins FS, Cohen PE. Meiotic arrest and aneuploidy in MLH3-deficient mice. Nat Genet 2002;31:385-90.



4. Lynch HT, Weisenburger DD, Quinn-Laquer B, Snyder CL, Lynch JF, Lipkin SM, Sanger WG. Family with acute myelocytic leukemia, breast, ovarian, and gastrointestinal cancer. Cancer Genet Cyto 2002;137:8-14.



5. Chen PC, Dudley S, Hagen W, Dizon D, Paxton L, Reichow D, Yoon SR, Yang K, Arnheim N, Liskay RM, Lipkin SM. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse. Cancer Res 2005;65:8662-70.



6. Frank SA, Chen PC, Lipkin SM. Kinetics of cancer: a method to test hypotheses of genetic causation. BMC Cancer 2005;5:163.



7. Chao EC, Lipkin SM. Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis. Nucleic Acids Res 2006;34:840-52.



8. Chao EC, Velasquez JL, Witherspoon MS, Rozek LS, Peel D, Ng P, Gruber SB, Watson P, Rennert G, Anton-Culver H, Lynch H, Lipkin SM. Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Hum Mutat 2008;29:852-60.



9. Chen PC, Kuraguchi M, Velasquez J, Wang Y, Yang K, Edwards R, Gillen D, Edelmann W, Kucherlapati R, Lipkin SM. Novel roles for MLH3 deficiency and TLE6-like amplification in DNA mismatch repair-deficient gastrointestinal tumorigenesis and progression. PLoS Genet 2008;4:e1000092.



10. Edwards RA, Witherspoon M, Wang K, Afrasiabi K, Pham T, Birnbaumer L, Lipkin SM. Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. Cancer Res 2009;69:6423-9.



11. Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML, Lipkin SM. Notch signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 2010;70:1469-78.



12. Sikandar S, Dizon D, Shen X, Li Z, Besterman J, Lipkin SM. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget. 2010 Nov;1(7):596-605.



13. Shin, Y., Hency, B., Lipkin, SM, and Shen, X. Frequency Domain Analysis Reveals External Periodic Fluctuations Can Generate Sustained p53 Oscillation PLoS One. 2011;6(7):e22852.



14. Crous-Bou M, Rennert G, Salazar R, Rodriguez-Moranta F, Rennert HS, Lejbkowicz F, Kopelovich L, Lipkin SM, Gruber SB, Moreno V. Genetic polymorphisms in fatty acid metabolism genes and colorectal cancer.Mutagenesis. 2012 Mar;27(2):169-76.



15. Wang X, Wei X, Thijssen B, Das J, Lipkin SM, Yu H. Three-dimensional reconstruction of protein networks provides insight into human genetic disease Nat Biotechnol. 2012 Jan 15;30(2):159-64. PMID: 22252508